We are live on ! Find out more
EPRX

Eupraxia Pharmaceuticals
EPRX

27 hedge funds and large institutions have $75.3M invested in Eupraxia Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

650% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 2

591% more capital invested

Capital invested by funds: $10.9M → $75.3M (+$64.4M)

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

93% more funds holding

Funds holding: 14 → 27 (+13)

30.15% more ownership

Funds ownership: 5.48% → 35.63% (+30%)

Holders
27
Holders Change
+13
Holders Change %
+92.86%
% of All Funds
0.35%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
15
Increased
7
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BGC
Beutel, Goodman & Co
Ontario, Canada
+$22.1M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$7.35M
3
VC
Vivo Capital
California
+$7.35M
4
GPP
Great Point Partners
Connecticut
+$6.53M
5
ABG
Ally Bridge Group
New York
+$4.98M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$108K
2
SC
Scotia Capital
Ontario, Canada
-$76.7K
3
QC
Quadrature Capital
United Kingdom
-$61.4K
4
JP Morgan Chase
JP Morgan Chase
New York
-$12.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
BGC
1
Beutel, Goodman & Co
Ontario, Canada
$23.9M +$22.1M +4,058,899 New
Balyasny Asset Management
2
Balyasny Asset Management
Illinois
$7.96M +$7.35M +1,350,000 New
VC
3
Vivo Capital
California
$7.96M +$7.35M +1,350,000 New
SC
4
Scotia Capital
Ontario, Canada
$7.25M -$76.7K -14,104 -1%
GPP
5
Great Point Partners
Connecticut
$7.08M +$6.53M +1,200,000 New
ABG
6
Ally Bridge Group
New York
$5.4M +$4.98M +915,000 New
LGM
7
Logos Global Management
California
$5.31M +$4.9M +900,000 New
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$2.53M +$1.2K +220 +0.1%
VCIM
9
Velan Capital Investment Management
Georgia
$2.08M +$1.92M +352,000 New
AAA
10
Affinity Asset Advisors
New York
$1.77M +$1.63M +300,000 New
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$1.48M +$1.36M +250,000 New
UBS Group
12
UBS Group
Switzerland
$565K +$317K +58,257 +155%
ISL
13
Ingalls & Snyder LLC
New York
$349K +$119K +21,900 +59%
Bank of America
14
Bank of America
North Carolina
$269K +$180K +33,018 +263%
Goldman Sachs
15
Goldman Sachs
New York
$237K +$1.63K +300 +0.8%
Bank of Montreal
16
Bank of Montreal
Ontario, Canada
$219K – – –
Raymond James Financial
17
Raymond James Financial
Florida
$197K +$115K +21,161 +173%
GP
18
Guardian Partners
Canada
$147K +$131K +24,130 New
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$125K +$116K +21,400 New
JP Morgan Chase
20
JP Morgan Chase
New York
$97.2K -$12.2K -2,250 -12%
CIBC World Market
21
CIBC World Market
Ontario, Canada
$88.4K – – –
IWC
22
Integrated Wealth Concepts
Massachusetts
$70.8K +$65.3K +12,000 New
TWA
23
TCI Wealth Advisors
Arizona
$64.9K +$59.9K +11,000 New
TWC
24
TD Waterhouse Canada
Ontario, Canada
$56.2K – – –
FDCDDQ
25
Federation des caisses Desjardins du Quebec
Quebec, Canada
$51.6K +$49.5K +9,091 New
1
2

EPRX Hedge Fund Activity: Q3 2025 in Review

27 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q3 2025, worth a combined $75.3M — up 591% from $10.9M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new EPRX positions and 2 closed out — a net gain of 13 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Beutel, Goodman & Co, opening a new position worth an estimated $22.1M. The largest seller was Citadel Advisors, exiting entirely with an estimated $108K sold.

  • 27 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q3 2025, up from 14 in Q2 2025.
  • Funds reported $75.3M of Eupraxia Pharmaceuticals stock for Q3 2025, up 591% quarter-over-quarter.
  • 15 funds opened new Eupraxia Pharmaceuticals positions in Q3 2025 and 2 closed out, a net change of +13 holders.
  • The largest Eupraxia Pharmaceuticals buyer in Q3 2025 was Beutel, Goodman & Co, an estimated $22.1M added.
  • The largest Eupraxia Pharmaceuticals seller in Q3 2025 was Citadel Advisors, an estimated $108K sold.

Based on aggregated 13F filings for Q3 2025.